The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review

DOI record: { "DOI": "10.1038/s41429-021-00491-6", "ISSN": [ "0021-8820", "1881-1469" ], "URL": "http://dx.doi.org/10.1038/s41429-021-00491-6", "alternative-id": [ "491" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "20 October 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Revised", "name": "revised", "order": 2, "value": "9 November 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 3, "value": "10 November 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 4, "value": "21 December 2021" }, { "group": { "label": "Compliance with ethical standards", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "The authors declare no competing interests." }, { "label": "Free to read", "name": "free", "value": "This content has been made available to all." } ], "author": [ { "ORCID": "http://orcid.org/0000-0001-6510-6365", "affiliation": [], "authenticated-orcid": false, "family": "Zaidi", "given": "Asiya Kamber", "sequence": "first" }, { "ORCID": "http://orcid.org/0000-0001-8339-1868", "affiliation": [], "authenticated-orcid": false, "family": "Dehgani-Mobaraki", "given": "Puya", "sequence": "additional" } ], "container-title": [ "The Journal of Antibiotics" ], "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2021, 12, 21 ] ], "date-time": "2021-12-21T04:29:21Z", "timestamp": 1640060961000 }, "deposited": { "date-parts": [ [ 2022, 1, 24 ] ], "date-time": "2022-01-24T11:04:36Z", "timestamp": 1643022276000 }, "indexed": { "date-parts": [ [ 2022, 3, 25 ] ], "date-time": "2022-03-25T20:30:42Z", "timestamp": 1648240242587 }, "is-referenced-by-count": 2, "issn-type": [ { "type": "print", "value": "0021-8820" }, { "type": "electronic", "value": "1881-1469" } ], "issue": "2", "issued": { "date-parts": [ [ 2021, 12, 21 ] ] }, "journal-issue": { "issue": "2", "published-print": { "date-parts": [ [ 2022, 2 ] ] } }, "language": "en", "license": [ { "URL": "https://www.springer.com/tdm", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 12, 21 ] ], "date-time": "2021-12-21T00:00:00Z", "timestamp": 1640044800000 } }, { "URL": "https://www.springer.com/tdm", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 12, 21 ] ], "date-time": "2021-12-21T00:00:00Z", "timestamp": 1640044800000 } } ], "link": [ { "URL": "https://www.nature.com/articles/s41429-021-00491-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41429-021-00491-6", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41429-021-00491-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "page": "60-71", "prefix": "10.1038", "published": { "date-parts": [ [ 2021, 12, 21 ] ] }, "published-online": { "date-parts": [ [ 2021, 12, 21 ] ] }, "published-print": { "date-parts": [ [ 2022, 2 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.4414/smw.2020.20242.", "author": "R Gharebaghi", "doi-asserted-by": "publisher", "first-page": "w20242", "journal-title": "Swiss Med Wkly", "key": "491_CR1", "unstructured": "Gharebaghi R, Heidary F. COVID-19 and Iran: swimming with hands tied! Swiss Med Wkly. 2020;150:w20242. https://doi.org/10.4414/smw.2020.20242.", "volume": "150", "year": "2020" }, { "DOI": "10.2183/pjab.87.13.", "author": "A Crump", "doi-asserted-by": "publisher", "first-page": "13", "journal-title": "Proc Jpn Acad Ser B Phys Biol Sci", "key": "491_CR2", "unstructured": "Crump A, Ōmura S. Ivermectin, ‘wonder drug’ from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:13–28. https://doi.org/10.2183/pjab.87.13.", "volume": "87", "year": "2011" }, { "author": "LH Kircik", "first-page": "325", "journal-title": "J Drugs Dermatol", "key": "491_CR3", "unstructured": "Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016;15:325–32.", "volume": "15", "year": "2016" }, { "DOI": "10.1208/s12248-007-9000-9.", "author": "A Gonzalez Canga", "doi-asserted-by": "publisher", "first-page": "42", "journal-title": "AAPS J", "key": "491_CR4", "unstructured": "Gonzalez Canga A, et al. The pharmacokinetics and interactions of ivermectin in humans–a mini-review. AAPS J. 2008;10:42–6. https://doi.org/10.1208/s12248-007-9000-9.", "volume": "10", "year": "2008" }, { "DOI": "10.9734/jammr/2020/v32i1030512", "author": "BS Kumar", "doi-asserted-by": "publisher", "first-page": "30", "journal-title": "J Adv Med Med Res.", "key": "491_CR5", "unstructured": "Kumar BS, Jeyaraman M, Jain R, Anudeep TC. A wonder drug in the arsenal against COVID—19: medication evidence from ivermectin. J Adv Med Med Res. 2020;32:30–7.", "volume": "32", "year": "2020" }, { "DOI": "10.1016/j.tips.2013.03.004", "author": "N Novac", "doi-asserted-by": "publisher", "first-page": "267", "journal-title": "Trends Pharm Sci", "key": "491_CR6", "unstructured": "Novac N. Challenges and opportunities of drug repositioning. Trends Pharm Sci. 2013;34:267–72.", "volume": "34", "year": "2013" }, { "key": "491_CR7", "unstructured": "ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2021 [cited 10 November 2021]. Available from: https://clinicaltrials.gov/ct2/home Home - ClinicalTrials.gov." }, { "key": "491_CR8", "unstructured": "Activ6study.org. Activ-6 study. Activ6study.org; 2021. https://activ6study.org/." }, { "key": "491_CR9", "unstructured": "Principletrial.org. Join the PRINCIPLE Trial. Principletrial.org.; 2021. https://www.principletrial.org/." }, { "DOI": "10.1007/BF00637608", "author": "G Edwards", "doi-asserted-by": "publisher", "first-page": "681", "journal-title": "Eur J Clin Pharm", "key": "491_CR10", "unstructured": "Edwards G, Dingsdale A, Helsby N, Orme ML, Breckenridge AM. The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. Eur J Clin Pharm. 1988;35:681–4.", "volume": "35", "year": "1988" }, { "DOI": "10.1007/s40262-016-0467-3", "author": "L Verrest", "doi-asserted-by": "publisher", "first-page": "583", "journal-title": "Clin Pharmacokinet", "key": "491_CR11", "unstructured": "Verrest L, Dorlo TPC. Lack of clinical pharmacokinetic studies to optimize the treatment of neglected tropical diseases: a systematic review. Clin Pharmacokinet. 2017;56:583–606.", "volume": "56", "year": "2017" }, { "DOI": "10.1007/BF00316107.", "author": "U Klotz", "doi-asserted-by": "publisher", "first-page": "607", "journal-title": "Eur J Clin Pharmacol", "key": "491_CR12", "unstructured": "Klotz U, Ogbuokiri JE, Okonkwo PO. Ivermectin binds avidly to plasma proteins. Eur J Clin Pharmacol 1990;39:607–8. https://doi.org/10.1007/BF00316107.", "volume": "39", "year": "1990" }, { "DOI": "10.1111/joim.13208", "doi-asserted-by": "publisher", "key": "491_CR13", "unstructured": "Wu MA, Fossali T, et al. Hypoalbuminemia in COVID-19: assessing the hypothesis for underlying pulmonary capillary leakage. J Intern Med. 2021. https://doi.org/10.1111/joim.13208." }, { "key": "491_CR14", "unstructured": "World Health Organization. Application for inclusion of ivermectin on the WHO Model List of Essential Medicines (EML) and Model List of Essential Medicines for Children (EMLc). World Health Organization; 2016." }, { "DOI": "10.1016/j.pt.2020.10.005", "author": "RJ Martin", "doi-asserted-by": "publisher", "first-page": "48", "journal-title": "Trends Parasitol.", "key": "491_CR15", "unstructured": "Martin RJ, Robertson AP, Choudhary S. Ivermectin: an anthelmintic, an insecticide, and much more. Trends Parasitol. 2021;37:48–64. https://doi.org/10.1016/j.pt.2020.10.005.", "volume": "37", "year": "2021" }, { "DOI": "10.4269/ajtmh.17-0042.", "author": "RE Chandler", "doi-asserted-by": "publisher", "first-page": "382", "journal-title": "Am J Trop Med Hyg", "key": "491_CR16", "unstructured": "Chandler RE. Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis? Am J Trop Med Hyg. 2018;98:382–8. https://doi.org/10.4269/ajtmh.17-0042.", "volume": "98", "year": "2018" }, { "DOI": "10.1016/j.cell.2020.03.045.", "author": "Q Wang", "doi-asserted-by": "publisher", "journal-title": "Cell", "key": "491_CR17", "unstructured": "Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020. https://doi.org/10.1016/j.cell.2020.03.045.", "year": "2020" }, { "DOI": "10.1016/j.chom.2020.02.001", "doi-asserted-by": "publisher", "key": "491_CR18", "unstructured": "Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020. https://doi.org/10.1016/j.chom.2020.02.001." }, { "DOI": "10.1016/j.virol.2013.11.040", "author": "AM Mielech", "doi-asserted-by": "publisher", "first-page": "64", "journal-title": "Virology.", "key": "491_CR19", "unstructured": "Mielech AM, Kilianski A, Baez-Santos YM, Mesecar AD, Baker SC. MERS-CoV papain-like protease has deISGylating and deubiquitinating activities. Virology. 2014;450–451:64–70.", "volume": "450–451", "year": "2014" }, { "key": "491_CR20", "unstructured": "Lehigh.edu. BioS 353. Lehigh.edu; 2021. https://www.lehigh.edu/~jas0/V14.html." }, { "DOI": "10.21873/invivo.12134", "author": "S Lehrer", "doi-asserted-by": "publisher", "first-page": "3023", "journal-title": "In Vivo.", "key": "491_CR21", "unstructured": "Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. In Vivo. 2020;34:3023–6. https://doi.org/10.21873/invivo.12134.", "volume": "34", "year": "2020" }, { "DOI": "10.3389/fmicb.2020.592908", "author": "AF Eweas", "doi-asserted-by": "publisher", "first-page": "592908.", "journal-title": "Front Microbiol.", "key": "491_CR22", "unstructured": "Eweas AF, Alhossary AA, Abdel-Moneim AS. Molecular docking reveals ivermectin and remdesivir as potential repurposed drugs against SARS-CoV-2. Front Microbiol. 2021;11:592908. https://doi.org/10.3389/fmicb.2020.592908.", "volume": "11", "year": "2021" }, { "DOI": "10.2217/fvl-2020-0342", "doi-asserted-by": "publisher", "key": "491_CR23", "unstructured": "Choudhury A, Das NC, Patra R, Bhattacharya M, Ghosh P, Patra BC, et al. Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach. Future Virol. 2021. https://doi.org/10.2217/fvl-2020-0342." }, { "DOI": "10.1016/j.bbamcr.2011.03.019", "author": "A Fulcher", "doi-asserted-by": "publisher", "first-page": "2176", "journal-title": "Biochem Biophys Acta Mol Cell Res.", "key": "491_CR24", "unstructured": "Fulcher A, Jans DA. Regulation of nucleocytoplasmic trafficking of viral proteins; an integral role in pathogenesis? Biochem Biophys Acta Mol Cell Res. 2011;1813:2176–90.", "volume": "1813", "year": "2011" }, { "DOI": "10.1016/j.antiviral.2020.104760", "author": "SNY Yang", "doi-asserted-by": "publisher", "first-page": "104760", "journal-title": "Antivir Res.", "key": "491_CR25", "unstructured": "Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antivir Res. 2020;177:104760.", "volume": "177", "year": "2020" }, { "DOI": "10.1016/B978-0-12-387738-3.00004-4", "doi-asserted-by": "crossref", "key": "491_CR26", "unstructured": "Freedman JC. Chapter 4—Ionophores in planar lipid bilayers. In: Sperelakis N, editor. Cell physiology sourcebook. Essentials of membrane biophysics, 4th ed. London, UK; Waltham, MA, USA; San Diego, CA, USA: Academic Press; 2012. p. 61–6." }, { "DOI": "10.1007/s00210-020-01902-5.", "author": "E Rizzo", "doi-asserted-by": "publisher", "first-page": "1153", "journal-title": "Naunyn Schmiedebergs Arch Pharm", "key": "491_CR27", "unstructured": "Rizzo E. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Naunyn Schmiedebergs Arch Pharm. 2020;393:1153–6. https://doi.org/10.1007/s00210-020-01902-5.", "volume": "393", "year": "2020" }, { "DOI": "10.5772/intechopen.99813", "doi-asserted-by": "publisher", "key": "491_CR28", "unstructured": "Dueñas-González A, Juárez-Rodríguez M. Ivermectin: potential repurposing of a versatile antiparasitic as a novel anticancer. In: Raymond C, Dalgleish A, editors. Repurposed drugs for cancer. IntechOpen; 2021. https://doi.org/10.5772/intechopen.99813." }, { "DOI": "10.3892/mmr.2017.8231.", "author": "G Dominguez‑Gomez", "doi-asserted-by": "publisher", "first-page": "3397", "journal-title": "Mol Med Rep", "key": "491_CR29", "unstructured": "Dominguez‑Gomez G, Chavez‑Blanco A, Medina‑Franco JL, Saldivar‑Gonzalez F, Flores‑Torrontegui Y, Juarez M, et al. Ivermectin as an inhibitor of cancer stem‑like cells. Mol Med Rep. 2018;17:3397–403. https://doi.org/10.3892/mmr.2017.8231.", "volume": "17", "year": "2018" }, { "DOI": "10.1038/s41429-020-0336-z.", "author": "F Heidary", "doi-asserted-by": "publisher", "first-page": "593", "journal-title": "J Antibiot", "key": "491_CR30", "unstructured": "Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot. 2020;73:593–602. https://doi.org/10.1038/s41429-020-0336-z.", "volume": "73", "year": "2020" }, { "DOI": "10.1177/1087057110390360.", "author": "KM Wagstaff", "doi-asserted-by": "publisher", "first-page": "192", "journal-title": "J Biomol Screen", "key": "491_CR31", "unstructured": "Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA. An AlphaScreen(R)-based assay for high-throughput screening for specific inhibitors of nuclear import. J Biomol Screen. 2011;16:192–200. https://doi.org/10.1177/1087057110390360.", "volume": "16", "year": "2011" }, { "DOI": "10.1016/j.virol.2014.10.013.", "author": "SM Bennett", "doi-asserted-by": "publisher", "first-page": "110", "journal-title": "Virology", "key": "491_CR32", "unstructured": "Bennett SM, Zhao L, Bosard C, Imperiale MJ. Role of a nuclear localization signal on the minor capsid proteins VP2 and VP3 in BKPyV nuclear entry. Virology. 2015;474:110–6. https://doi.org/10.1016/j.virol.2014.10.013.", "volume": "474", "year": "2015" }, { "DOI": "10.3390/microorganisms8030409", "doi-asserted-by": "publisher", "key": "491_CR33", "unstructured": "Raza S, Shahin F, Zhai W, et al. Ivermectin inhibits bovine herpesvirus 1 DNA polymerase nuclear import and interferes with viral replication. Microorganisms. 2020;8. https://doi.org/10.3390/microorganisms8030409." }, { "DOI": "10.1016/j.antiviral.2020.104787", "doi-asserted-by": "publisher", "key": "491_CR34", "unstructured": "Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;104787. https://doi.org/10.1016/j.antiviral.2020.104787." }, { "DOI": "10.1002/cpt.1909", "doi-asserted-by": "publisher", "key": "491_CR35", "unstructured": "Arshad U, Pertinez H, Box H, et al. Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1909." }, { "key": "491_CR36", "unstructured": "Yagisawa M, Foster PJ, Hanaki H, Ōmura S. Global trends in clinical studies of ivermectin in COVID-19. Jpn J Antibiotics. 2021;44:74-1." }, { "DOI": "10.21203/rs.3.rs-73308/v1", "doi-asserted-by": "publisher", "key": "491_CR37", "unstructured": "Swargiary A. Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: evidence from in silico studies. Research Square; 2020. https://doi.org/10.21203/rs.3.rs-73308/v1." }, { "DOI": "10.1038/s41579-020-00468-6.", "author": "P V’kovski", "doi-asserted-by": "publisher", "first-page": "155", "journal-title": "Nat Rev Microbiol", "key": "491_CR38", "unstructured": "V’kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19:155–70. https://doi.org/10.1038/s41579-020-00468-6.", "volume": "19", "year": "2021" }, { "DOI": "10.1073/pnas.1508686112", "author": "Y Ma", "doi-asserted-by": "publisher", "first-page": "9436", "journal-title": "Proc Natl Acad Sci USA", "key": "491_CR39", "unstructured": "Ma Y, Wu L, Shaw N, Gao Y, Wang J, Sun Y, et al. Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex. Proc Natl Acad Sci USA. 2015;112:9436–41.", "volume": "112", "year": "2015" }, { "DOI": "10.1038/s42003-020-01577-x", "author": "V Mody", "doi-asserted-by": "publisher", "first-page": "93", "journal-title": "Commun Biol", "key": "491_CR40", "unstructured": "Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert MCCJC, et al. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun Biol. 2021;4:93. https://doi.org/10.1038/s42003-020-01577-x.", "volume": "4", "year": "2021" }, { "DOI": "10.1093/emboj/16.23.7067", "author": "T Sekimoto", "doi-asserted-by": "publisher", "first-page": "7067", "journal-title": "EMBO J", "key": "491_CR41", "unstructured": "Sekimoto T, Imamoto N, Nakajima K, Hirano T, Yoneda Y. Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. EMBO J. 1997;16:7067–77.", "volume": "16", "year": "1997" }, { "DOI": "10.1016/j.celrep.2020.108185", "doi-asserted-by": "publisher", "key": "491_CR42", "unstructured": "Konno Y, Kimura I, Uriu K, Fukushi M, Irie T, Koyanagi Y, et al. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant. Cell Rep. 2020. https://doi.org/10.1016/j.celrep.2020.108185." }, { "DOI": "10.1093/infdis/jiaa356", "doi-asserted-by": "publisher", "key": "491_CR43", "unstructured": "Yang D, Chu H, Hou Y, Chai Y, Shuai H, Lee AC-Y, et al. Attenuated interferon and pro-inflammatory response in SARSCoV-2-infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. J Infect Dis. 2020. https://doi.org/10.1093/infdis/jiaa356." }, { "DOI": "10.1038/s41418-020-00633-7.", "author": "T Matsuyama", "doi-asserted-by": "publisher", "first-page": "3209", "journal-title": "Cell Death Differ", "key": "491_CR44", "unstructured": "Matsuyama T, Kubli SP, Yoshinaga SK, et al. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 2020;27:3209–25. https://doi.org/10.1038/s41418-020-00633-7.", "volume": "27", "year": "2020" }, { "DOI": "10.1371/journal.pone.0168170", "author": "C Seth", "doi-asserted-by": "publisher", "first-page": "e0168170", "journal-title": "PLoS ONE", "key": "491_CR45", "unstructured": "Seth C, Mas C, Conod A, Mueller J, Siems K, Kuciak M, et al. LongLasting WNT-TCF response blocking and epigenetic modifying activities of withanolide f in human cancer cells. PLoS ONE. 2016;11:e0168170.", "volume": "11", "year": "2016" }, { "DOI": "10.1016/j.chom.2020.05.008", "author": "A Park", "doi-asserted-by": "publisher", "first-page": "870", "journal-title": "Cell Host Microbe", "key": "491_CR46", "unstructured": "Park A, Iwasaki A, Type I. and type III interferons—induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27:870–8.", "volume": "27", "year": "2020" }, { "DOI": "10.1007/s00011-008-8007-8", "author": "X Zhang", "doi-asserted-by": "publisher", "first-page": "524", "journal-title": "Inflamm Res", "key": "491_CR47", "unstructured": "Zhang X, Song Y, Ci X, et al. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res. 2008;57:524–9. https://doi.org/10.1007/s00011-008-8007-8.", "volume": "57", "year": "2008" }, { "DOI": "10.1038/sigtrans.2017.23", "author": "T Liu", "doi-asserted-by": "publisher", "first-page": "17023", "journal-title": "Signal Transduct Target Ther", "key": "491_CR48", "unstructured": "Liu T, Zhang L, Joo D, Sun S-C. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023 https://doi.org/10.1038/sigtrans.2017.23.", "volume": "2", "year": "2017" }, { "DOI": "10.1186/s13046-019-1251-7", "author": "L Jiang", "doi-asserted-by": "publisher", "first-page": "265", "journal-title": "J Exp Clin Cancer Res", "key": "491_CR49", "unstructured": "Jiang L, Wang P, Sun YJ, Wu YJ. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res. 2019;38:265 https://doi.org/10.1186/s13046-019-1251-7.", "volume": "38", "year": "2019" }, { "DOI": "10.1136/bmj.m1443", "author": "S Zheng", "doi-asserted-by": "publisher", "first-page": "m1443", "journal-title": "BMJ.", "key": "491_CR50", "unstructured": "Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARSCoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ. 2020;369:m1443.", "volume": "369", "year": "2020" }, { "DOI": "10.1056/NEJMoa2015432", "doi-asserted-by": "publisher", "key": "491_CR51", "unstructured": "Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2015432." }, { "DOI": "10.1016/j.jinf.2020.04.021", "doi-asserted-by": "publisher", "key": "491_CR52", "unstructured": "Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.04.021." }, { "DOI": "10.3389/fimmu.2020.00827", "author": "B Diao", "doi-asserted-by": "publisher", "first-page": "827", "journal-title": "Front Immunol", "key": "491_CR53", "unstructured": "Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.", "volume": "11", "year": "2020" }, { "DOI": "10.1126/science.abc6027", "author": "J Hadjadj", "doi-asserted-by": "publisher", "first-page": "718", "journal-title": "Science.", "key": "491_CR54", "unstructured": "Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–24.", "volume": "369", "year": "2020" }, { "DOI": "10.1186/s12941-020-00362-2", "author": "W Chen", "doi-asserted-by": "publisher", "first-page": "18", "journal-title": "Ann Clin Microbiol Antimicrob.", "key": "491_CR55", "unstructured": "Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020;19:18.", "volume": "19", "year": "2020" }, { "DOI": "10.1124/pr.119.018440", "author": "U Bharadwaj", "doi-asserted-by": "publisher", "first-page": "486", "journal-title": "Pharm Rev", "key": "491_CR56", "unstructured": "Bharadwaj U, Kasembeli MM, Robinson P, Tweardy DJ. Targeting janus kinases and signal transducer and activator of transcription 3 to treat inflammation, fibrosis, and cancer: rationale, progress, and caution. Pharm Rev. 2020;72:486–526.", "volume": "72", "year": "2020" }, { "DOI": "10.1128/JVI.01012-07", "author": "M Frieman", "doi-asserted-by": "publisher", "first-page": "9812", "journal-title": "J Virol", "key": "491_CR57", "unstructured": "Frieman M, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/golgi membrane. J Virol. 2007;81:9812–24.", "volume": "81", "year": "2007" }, { "DOI": "10.3390/cancers11101527", "author": "J-H Kim", "doi-asserted-by": "publisher", "first-page": "1527", "journal-title": "Cancers.", "key": "491_CR58", "unstructured": "Kim J-H, Choi HS, Kim S-L, Lee D-S. The PAK1-Stat3 signaling pathway activates IL-6 gene transcription and human breast cancer stem cell formation. Cancers. 2019;11:1527.", "volume": "11", "year": "2019" }, { "DOI": "10.1158/0008-5472.CAN-15-2887", "author": "Q Dou", "doi-asserted-by": "publisher", "first-page": "4457", "journal-title": "Cancer Res", "key": "491_CR59", "unstructured": "Dou Q, Chen H-N, Wang K, Yuan K, Lei Y, Li K, et al. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. Cancer Res. 2016;76:4457–69.", "volume": "76", "year": "2016" }, { "DOI": "10.15252/emmm.202114122.", "author": "GD De Melo", "doi-asserted-by": "publisher", "first-page": "e14122", "journal-title": "EMBO Mol Med", "key": "491_CR60", "unstructured": "De Melo GD, Lazarini F, Larrous F, et al. Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin. EMBO Mol Med. 2021;13:e14122. https://doi.org/10.15252/emmm.202114122.", "volume": "13", "year": "2021" }, { "DOI": "10.1085/jgp.200308986", "author": "A Priel", "doi-asserted-by": "publisher", "first-page": "281", "journal-title": "J Gen Physiol.", "key": "491_CR61", "unstructured": "Priel A, Silberberg SD. Mechanism of ivermectin facilitation of human P2X4 receptor channels. J Gen Physiol. 2004;123:281–93. https://doi.org/10.1085/jgp.200308986.", "volume": "123", "year": "2004" }, { "DOI": "10.3389/fphar.2017.00291.", "author": "L Stokes", "doi-asserted-by": "publisher", "first-page": "291", "journal-title": "Front Pharm", "key": "491_CR62", "unstructured": "Stokes L, Layhadi JA, Bibic L, Dhuna K, Fountain SJ. P2X4 receptor function in the nervous system and current breakthroughs in pharmacology. Front Pharm. 2017;8:291. https://doi.org/10.3389/fphar.2017.00291.", "volume": "8", "year": "2017" }, { "DOI": "10.4049/jimmunol.1700965.", "author": "JA Layhadi", "doi-asserted-by": "publisher", "first-page": "1159", "journal-title": "J Immunol.", "key": "491_CR63", "unstructured": "Layhadi JA, Turner J, Crossman D, Fountain SJ. ATP evokes Ca2+ responses and CXCL5 secretion via P2X4 receptor activation in human monocyte-derived macrophages. J Immunol. 2018;200:1159. https://doi.org/10.4049/jimmunol.1700965.", "volume": "200", "year": "2018" }, { "DOI": "10.1186/s10020-020-00172-4pmid", "doi-asserted-by": "publisher", "key": "491_CR64", "unstructured": "Andersson U, Ottestad W, Tracey KJ. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? Mol Med. 2020;26:42. https://doi.org/10.1186/s10020-020-00172-4pmid." }, { "author": "M Juarez", "first-page": "317", "journal-title": "Am J Cancer Res.", "key": "491_CR65", "unstructured": "Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res. 2018;8:317–31.", "volume": "8", "year": "2018" }, { "DOI": "10.1016/S1473-3099(20)30293-0", "author": "MS Xydakis", "doi-asserted-by": "publisher", "first-page": "1015", "journal-title": "Lancet Infect Dis.", "key": "491_CR66", "unstructured": "Xydakis MS, Dehgani-Mobaraki P, Holbrook EH, et al. Smell and taste dysfunction in patients with COVID-19. Lancet Infect Dis. 2020;20:1015–6. https://doi.org/10.1016/S1473-3099(20)30293-0.", "volume": "20", "year": "2020" }, { "DOI": "10.1111/j.1472-8206.2009.00684.x", "author": "X Ci", "doi-asserted-by": "publisher", "first-page": "449", "journal-title": "Fundam Clin Pharm", "key": "491_CR67", "unstructured": "Ci X, Li H, Yu Q. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharm. 2009;23:449–55.", "volume": "23", "year": "2009" }, { "DOI": "10.1007/s00011-011-0307-8", "author": "S Yan", "doi-asserted-by": "publisher", "first-page": "589", "journal-title": "Inflamm Res", "key": "491_CR68", "unstructured": "Yan S, Ci X, Chen N. Anti-inflammatory effects of ivermectin in mouse model of allergic asthma. Inflamm Res. 2011;60:589–96.", "volume": "60", "year": "2011" }, { "DOI": "10.30459/2020-24", "doi-asserted-by": "publisher", "key": "491_CR69", "unstructured": "Zaidi AK, Dawoodi S, Pirro M, Monti M, Mobaraki PD. Key role of annexin A2 and plasmin in COVID-19 pathophysiology, clinical presentation and outcomes—a review. Ital J Prev, Diagn Ther Med. 2020;3. https://doi.org/10.30459/2020-24." }, { "DOI": "10.2139/ssrn.3636557", "doi-asserted-by": "crossref", "key": "491_CR70", "unstructured": "Scheim DE. Ivermectin for COVID-19 Treatment: Clinical Response at Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated Vascular Occlusion (June 26, 2020). Available at SSRN: https://ssrn.com/abstract=3636557." }, { "DOI": "10.1038/s41569-020-0360-5.", "author": "YY Zheng", "doi-asserted-by": "publisher", "first-page": "259", "journal-title": "Nat Rev Cardiol", "key": "491_CR71", "unstructured": "Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259–60. https://doi.org/10.1038/s41569-020-0360-5.", "volume": "17", "year": "2020" }, { "DOI": "10.1016/j.ebiom.2017.09.022", "author": "H Nagai", "doi-asserted-by": "publisher", "first-page": "147", "journal-title": "EBioMedicine.", "key": "491_CR72", "unstructured": "Nagai H, Satomi T, Abiru A, Miyamoto K, Nagasawa K, Maruyama M, et al. Antihypertrophic effects of small molecules that maintain mitochondrial ATP levels under hypoxia. EBioMedicine. 2017;24:147–58. https://doi.org/10.1016/j.ebiom.2017.09.022.", "volume": "24", "year": "2017" } ], "reference-count": 72, "references-count": 72, "relation": {}, "score": 1, "short-container-title": [ "J Antibiot" ], "short-title": [], "source": "Crossref", "subject": [ "Drug Discovery", "Pharmacology" ], "subtitle": [], "title": [ "The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review" ], "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "75" }